TARA
Protara Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.52
+1.20%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -31.0%
- EBIT
- -33.9%
- EPS
- +16.0%
- Free cash flow
- -48.5%
- Operating cash flow
- -47.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -33.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- -28.9%
- EBIT
- -31.3%
- Net income
- -28.8%
- EPS
- +38.2%
- Free cash flow
- -57.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026